News

Akebia Therapeutics Unveils Key Research Findings at ASN Kidney Week

Akebia Therapeutics Unveils Key Research Findings at ASN Kidney Week

Akebia Therapeutics at ASN Kidney Week 2025

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a dedicated biopharmaceutical organization specializing in kidney disease, proudly announces its participation in the American Society of Nephrology Kidney Week 2025. This major event is a hotspot for nephrology professionals and takes place in Houston, emphasizing the latest findings in kidney health.

Noteworthy Presentations by Akebia

During this esteemed gathering, notable presentations will highlight the latest clinical data related to vadadustat, Akebia's pioneering treatment for anemia stemming from chronic kidney disease (CKD). Dr. Glenn M. Chertow of Stanford University will lead the presentation of a critical win odds analysis related to mortality and hospitalization among patients enrolled in the INNO2VATE trials, a global Phase 3 clinical program aimed at assessing the efficacy of vadadustat.

Understanding Vadadustat

Vadadustat operates as a hypoxia-inducible factor prolyl hydroxylase inhibitor, influencing the body’s natural responses to low oxygen levels. This treatment notably stimulates the production of erythropoietin, crucial for hemoglobin and red blood cell production, thus managing anemia in CKD patients. Following its U.S. approval for use among adults on dialysis, Akebia continues to expand on its promising research.

Engagement with the Nephrology Community

Steven Burke, MD, Senior Vice President and Chief Research & Development Officer at Akebia, shared insights on their ongoing commitment: "Our engagement with the nephrology community plays a critical role in clarifying the treatment landscape. Achieving transparent data-sharing guarantees that healthcare professionals are equipped with essential knowledge to make informed therapeutic decisions."

Key Oral Presentation Details

Among the highlights of the ASN Kidney Week will be an oral presentation discussing:

Win-Odds Analysis of Deaths and Hospitalization in Patients Taking Vadadustat or Darbepoetin Alfa for CKD-related Anemia Undergoing Dialysis
Presenter: Glenn M. Chertow, MD
Session Date/Time: November 6, 2025; 4:30 PM to 6:00 PM
Session Room: Room 351D (Convention Center)

Poster Presentations at ASN Kidney Week

Additionally, Akebia will feature several poster presentations relevant to vadadustat:

Model-Based VAFSEO Starting Dose Recommendations in Dialysis-Dependent CKD Patients
Poster #: TH-PO902
November 6, 2025; 10:00 AM-12:00 PM CDT

Vadadustat Outcomes In-Center Experience (VOICE) Study: A Pragmatic Randomized Controlled Trial Testing Safety of Three Times Weekly Vadadustat
Poster #: FR-PO0204
November 7, 2025; 10:00 AM-12:00 PM CDT

Consistency of the Estimate of Responsiveness of Vadadustat vs. Darbepoetin
Poster #: FR-PO0202
November 7, 2025; 10:00 AM-12:00 PM CDT

Three Times Weekly In-Center Vadadustat vs. Standard Care Erythropoiesis-Stimulating Agent for CKD-Related Anemia in Patients Undergoing Dialysis (VOCAL)
Poster #: INFO10-FR
November 7, 2025; 10:00 AM-12:00 PM CDT

About Akebia Therapeutics

Founded in 2007, Akebia Therapeutics is intent on transforming the treatment landscape for those affected by kidney disease. With headquarters located in Cambridge, Massachusetts, the organization focuses on providing innovative, evidenced-based solutions. Interested individuals can find more about Akebia's mission by visiting their website.

About Vafseo (vadadustat) Tablets

As a once-daily oral treatment, Vafseo serves as a valuable option for managing anemia in CKD patients, activated through the body’s natural mechanisms to boost red blood cell production. It is notably available in over 37 countries.

Frequently Asked Questions

What is Akebia Therapeutics?

Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of those with kidney disease through innovative treatments and research.

What will Akebia present at ASN Kidney Week 2025?

Akebia will present key findings from clinical data on vadadustat, focusing on its benefits for CKD-related anemia.

Who is leading the oral presentation?

Dr. Glenn M. Chertow of Stanford University will present a crucial analysis on the impact of vadadustat.

What is Vafseo?

Vafseo (vadadustat) is a medication designed to manage anemia in CKD patients by enhancing the body’s natural production of red blood cells.

Where can I learn more about Akebia?

For more information, visit Akebia Therapeutics’ official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Chery Auto's Bold Green Tech Showcase at 2026 Summit

Updated Category News Views 3

Chery Auto Puts Eco Tech at Front and Center You know, Chery Auto isn't just manufacturing cars anymore—it's shaping an entire lifestyle. For the uninitiated, they’re calling in everyone worth knowing to their headquarters in Wuhu, China, come October 18 through 24. The 2026 Chery International User Summit is kind of a big deal this year with nearly 20 new green...

Continue Reading
GAC's Cambodia Plant: A Strategic Manufacturing Shift

Updated Category News Views 3

Setting the Stage for New Industrial Growth On September 17, a milestone was etched in the sands of Cambodia when the GAC Cambodia KD Plant officially flipped the switch. This ain't just another factory throwing doors open; it's a fresh chapter in regional manufacturing power plays. We had some big hitters in attendance, like Cambodian Prime Minister Hun Manet, showing...

Continue Reading
Papa John's Faces Class Action Over Misleading Info

Updated Category News Views 5

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Continue Reading
China's Tech Success Echoes in Global Living Rooms

Updated Category News Views 4

A New Player in Global Tech If you've been sleeping on China's tech scene, it's time to wake up. Moonshot AI just launched Kimi K3, the largest open-source model by parameters we've seen, a significant leap in artificial intelligence that's catching even the eyes of folks who hardly touch technology—like retirees in Italy. Rapid AI Advancements China's story isn't about...

Continue Reading
Xi Jinping Thought: A Bold Prospect for Future Governance

Updated Category News Views 5

107 years in the game, and the Communist Party of China (CPC) isn't showing any signs of slowing. With their recent conference in Beijing focusing on Xi Jinping Thought on Party Building, it’s clear they’ve got their eyes on the future, not just resting on past laurels. This Xi Jinping Thought is about a thorough self-improvement plan for the Party, a clear strategy...

Continue Reading
BarrelPick.com Launches for Bourbon Aficionados

Updated Category News Views 4

Just when you think you've seen all the ways to enjoy bourbon, along comes BarrelPick.com with a tantalizing new proposition. They're throwing down the gauntlet for bourbon lovers everywhere by letting you buy an entire barrel, let it sit around for a bit, watch it mature, and then call the shots on when it finally sees the light of day in a bottle. Talk about skipping...

Continue Reading
Flying Car Regulatory Sandbox Begins in UAE

Updated Category News Views 7

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

Continue Reading
Quay Dominates 2026 Sunglasses Review for Variety

Updated Category News Views 4

Sunglasses Designed for Every Face Type When it comes to picking the right pair of shades, face shape is only part of the equation. Expert Consumers just dropped their 2026 verdict, spotlighting Quay as the go-to brand for those wider faces, tricky nose bridges, and the noggins that run a tad larger than average. Forget what you heard about one-size-fits-all. This...

Continue Reading
PayPal Under Investigation: Legal Battles Intensify

Updated Category News Views 3

A Bumpy Ride for PayPal's Investors Back in 2025, PayPal was beaming about new growth strategies, filling the air with grandiose promises. Fast forward to February 2026, and the script had flipped entirely. Earnings came in nasty and disappointing, particularly in the Branded Checkout front. Adding to the chaos was their CEO unceremoniously taking the high road out the...

Continue Reading
Why Liver Nurture Taps into Health Sector Trends

Updated Category News Views 5

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

Continue Reading

Top 5 Most Recently Viewed Articles

Trump's Bold Move: Potential Tariffs on Cars from Mexico

Updated Category News Views 60

Trump's Proposed Tariffs on Mexican Cars During a rally with his supporters, Donald Trump, a key Republican presidential candidate, unveiled a bold proposal that could have a major impact on trade relations. He announced that if he wins the upcoming election, he plans to impose a staggering 100% tariff on all vehicles coming into the United States from Mexico. Details of...

Continue Reading
Understanding Immigration Policy's Impact on Rideshare Services

Updated Category News Views 1117

Understanding the Impact of Immigration Policies on Rideshare The gig economy, especially in rideshare and food delivery services, has been a topic of much discussion, particularly with the emergence of new immigration policies. Uber Technologies Inc (NYSE: UBER), Lyft, and DoorDash are particularly noteworthy examples. Industry experts from Wolfe Research recently...

Continue Reading
Join the Class Action Against DexCom, Inc. for Investor Recovery

Updated Category News Views 108

Understanding the DexCom Class Action Lawsuit The Gross Law Firm is reaching out to shareholders of DexCom, Inc. (NASDAQ: DXCM) with an important announcement. If you purchased shares within a specified timeframe, it's crucial to understand your rights and the steps to potentially join a class action lawsuit aimed at recovering losses. Who Should Be Involved? If you...

Continue Reading
Armanino's New Services Empower Firms to Navigate Challenges

Updated Category News Views 179

Armanino Launches Comprehensive Support for Professional Services Armanino, a leading name in accounting and consulting, has announced the establishment of its innovative strategic industry group focused specifically on delivering specialized tax, accounting, consulting, and advisory services for various professional service organizations. This initiative emphasizes...

Continue Reading
Exploring UniFirst's Expected Earnings Performance

Updated Category News Views 144

Understanding UniFirst's Upcoming Earnings Announcement UniFirst (NASDAQ: UNF) is set to disclose its quarterly earnings soon, drawing considerable attention from investors and analysts alike. The anticipation revolves around the projected earnings per share (EPS) of $2.07, serving as a benchmark for evaluating the company's performance against analyst expectations. What...

Continue Reading